A buy-in offer reaches a pediatrician at the most financially crowded moment of her life, in a generation where employment is the default and ownership is the argument that has to be made. What she weighs is not one question but five — the price, the derivation, the return, the debt, and the exit — and the practice that wants her yes answers them before she has to ask.
The offer usually arrives as a compliment. Three years in, the practice likes her, the families ask for her by name, and at the end of an ordinary Thursday one of the partners says the thing partners say: the group would like her to think about buying in. It is meant as the best news the practice can offer, and the partners are often puzzled when the reaction is not joy but a careful, guarded quiet. The quiet has a good explanation. The offer has landed on the most financially crowded balance sheet she will ever carry.
The pediatrician weighing partnership is typically in her late thirties or early forties. Medical school debt is still amortizing. The mortgage has decades to run. The college funds exist mostly as intentions. Against that backdrop, a six-figure buy-in does not read as an opportunity; it reads as one obligation too many, and more than one good candidate has walked away from ownership on the sticker alone. The practice that treats her hesitation as timidity has misread the room. Her hesitation is arithmetic, and arithmetic is exactly the language the practice should be prepared to answer in.
It should also understand what it is competing against, because the alternative on her side of the table is effortless. Across the decade from 2012 to 2022, private practice's share of physicians fell from 60.1 percent to 46.7 percent, and the decline was driven not by mid-career owners selling but by new physicians choosing employment. Under-45 physicians are now employees by a wide margin. Employment is her generation's default — the path that requires no check, no note, and no meeting. Ownership is the path that has to make its case. A practice that wants internal succession can no longer wait for a buyer to emerge from the associate ranks on her own; it has to build one, and building one starts with taking her five questions seriously.
The first question is the least asked out loud and the most important: what, exactly, does the check purchase? The honest answer begins with what it does not. An outside buyer — a private-equity firm, a hospital system — pays its multiple because it acquires control, scale synergies, and the right to reprice the practice's future. The incoming partner receives none of those. She is buying a minority seat in an illiquid asset with one realistic future buyer, which is why the internal buy-in market is not the outside market, and why pricing an internal admission at outside-buyer multiples kills admissions. What the seat does buy is the ownership premium: owner earnings above the employed-physician equivalent — the difference between what she makes as an employee and what an owner of similar productivity takes home. That premium is the product. Everything else in the deal is packaging.
The second question is about the derivation, and it is the one candidates are most afraid to ask. A figure presented as "what everyone paid," arriving without a worked example, puts her in an impossible position: accept a six-figure number she cannot check, or ask enough questions to check it and worry that the asking reads as a lack of commitment. Practices resolve this with disclosure discipline. The methodology and a worked example belong in the admission conversation, computed from the practice's actual books rather than a projection, presented before she has to request them. A candidate shown the derivation can say yes with her eyes open — and the signature of a partner who understood what she signed is worth more, for decades, than the signature of one who was talked past her doubts.
The third question deserves a number, not a mood. Priced correctly, a buy-in is an investment rather than a purchase: if a $150,000 buy-in raises the physician's annual earnings by $30,000 to $50,000 — the ordinary consequence of moving from employed compensation to a partner's share of distributions — the investment returns 20 to 33 percent per year once the note is retired, before any appreciation in the equity itself. The candor matters as much as the arithmetic. A $200,000 note at 8 percent consumes $16,000 of the first year's differential, so the full return arrives only when the note does; the payback runs about four years on the differential alone. And the risks that justify that premium return should be named rather than waved away: illiquidity, a single future buyer, and capital at real risk are precisely why partnership must pay better than an index fund. Few investments available to a physician at any stage of life return anything close — and none of the others comes with a vote.
The same arithmetic protects her from a bad offer, which is why practices should run it against themselves first. A $600,000 buy-in that moves the incoming physician from $180,000 to $240,000 is a ten-year payback before financing costs — not a defensible return, and a number that fails from either chair. A price the candidate's arithmetic rejects is a price the practice should reject too.
The fourth question is where the sticker meets the household budget, and the answer starts by inverting the usual logic: what the buyer can afford to service is part of what prices the deal. Determine what the practice earns, what the incoming partner must reasonably take home, and what operations cost; the residual is available for debt service, and debt service disciplines the price — $50,000 a year of available debt service supports, at 9 percent over five years, a purchase near $194,000. When the formula value runs above the affordable value, the gap closes through terms — longer notes, seller financing, sliding equity, phased tranches — never through fantasy compensation projections. The instruments each carry a governing rule: bank financing pays the sellers in full but loads a young pediatrician with personal-guaranteed debt; a seller note spreads the price and aligns the sellers with the transition, provided the promissory note, security, and offset terms are in writing; salary-differential and equity-in-lieu-of-bonus structures fund the buy-in from compensation the practice would have paid anyway — with the tax character modeled by both sides' accountants before anyone agrees, because a structure that works pre-tax and fails after-tax is discovered at the worst possible time.
The fifth question is really two. On timing: a stated associate period of two to three years, governed by objective criteria rather than mood, with the sharpest criterion gating the option on recovered investment — the option opens once the practice has earned roughly $150,000 to $300,000 of cumulative profit from her employment — which converts "when do I make partner" from a feelings conversation into a ledger everyone can read. On the exit: the symmetry principle, which requires that whatever methodology prices the way in also prices the way out, maintained by an annual value update signed by every partner. And in between sits the variable most agreements omit entirely — what keeping the seat requires: the work commitment, call participation, credentials, management duty, and conduct that full partnership assumes. She deserves all of it in writing before the check, because the offer she is really evaluating is not a price. It is a governance system, and the buy-in is simply her ticket into it.
One more thing changes at the signature, and naming it in advance prevents a decade of quiet resentment: the buy-in settles the ledger. The price the founders set monetizes the early years — the undercapitalized winters, the call nobody shared, the salaries deferred to make payroll — and once the check clears, little remains owed for them. A founder who believes the sacrifice was worth more than the price should raise the price, not the grievance, and then honor the sale.
The candidates who say yes to partnership are not braver than the ones who walk. They were shown more. A practice that wants its next partner answers the five questions before they are asked — with its own numbers, in writing, from both chairs.
Most often on the sticker alone. The offer reaches a pediatrician at the most financially crowded moment of her life — student debt amortizing, a mortgage with decades to run, college funds still mostly intentions — and a six-figure number without a worked derivation reads as one obligation too many. The practices that convert candidates answer the arithmetic before it is asked.
Priced as an investment, a buy-in that raises annual earnings by $30,000 to $50,000 on a $150,000 price returns 20 to 33 percent per year once the note is retired — a premium that exists because the equity is illiquid, has a single realistic future buyer, and puts capital at real risk. A price that produces a ten-year payback fails the test from either chair.
After a stated associate period, commonly two to three years, governed by objective criteria — productivity thresholds, board certification, practice citizenship, insurability — with the sharpest criterion gating the option on recovered investment: roughly $150,000 to $300,000 of cumulative profit generated for the practice. The gate converts the timing question into a ledger rather than a feelings conversation.
The Partnership Agreement Analyzer scores an existing agreement against the framework this series is built on — or schedule a discovery call to work through it with PMI. The full framework, with the arithmetic, lives in the textbook Pediatric Practice Management: The Fundamentals.